Literature DB >> 7562962

Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease.

J Jankovic1, J Beach, T Ashizawa.   

Abstract

The potential impact of DNA testing on asymptomatic subjects at risk for Huntington's disease (HD) has been addressed by numerous studies, but the effect of revealing the genetic results to patients with a clinically established diagnosis of HD has not been previously evaluated. We studied 36 patients, with equal distribution of men and women, mean age 53.9 (SD 12.3) years (range 25-76) and mean duration of symptoms of 11.2 (SD 7.7) years (range 2-33), whose clinical diagnosis of HD was confirmed by expanded CAG repeats (> 40). Coping strategies and depression levels were assessed before the results of DNA testing were imparted. The assessments were repeated two weeks and three months after the results were explained to the patients and their relatives and were compared to the baseline assessments. This group of HD patients was compared with 10 patients who had similar symptoms but the diagnosis of HD was excluded by normal CAG repeats (< 30). Although some patients with HD expressed a subjective reaction to the positive result (four were "surprised", one was "frustrated", and one "devastated"), there were no differences in any psychological scores including Beck Depression Inventory, functional capacity, symptom interference, independence scale, and other measures of mood and behaviour two weeks and three months later. Similarly, no change was noted in any of these measures in the non-HD group. These results suggest that mood and coping strategies are unaffected by DNA confirmation of diagnosis in symptomatic patients with HD.

Entities:  

Mesh:

Year:  1995        PMID: 7562962      PMCID: PMC1050542          DOI: 10.1136/jmg.32.7.516

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs.

Authors:  I Shoulson
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

3.  A polymorphic DNA marker genetically linked to Huntington's disease.

Authors:  J F Gusella; N S Wexler; P M Conneally; S L Naylor; M A Anderson; R E Tanzi; P C Watkins; K Ottina; M R Wallace; A Y Sakaguchi
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

4.  CAG repeat size and clinical presentation in Huntington's disease.

Authors:  T Ashizawa; L J Wong; C S Richards; C T Caskey; J Jankovic
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

5.  The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing.

Authors:  S Wiggins; P Whyte; M Huggins; S Adam; J Theilmann; M Bloch; S B Sheps; M T Schechter; M R Hayden
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

6.  Incidence and prevalence of Huntington's disease in Olmsted County, Minnesota (1950 through 1989).

Authors:  E Kokmen; F S Ozekmekçi; C M Beard; P C O'Brien; L T Kurland
Journal:  Arch Neurol       Date:  1994-07

Review 7.  The neurogenetics genie: testing for the Huntington's disease mutation.

Authors:  S Hersch; R Jones; W Koroshetz; K Quaid
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

8.  Predictive testing for Huntington's disease with use of a linked DNA marker.

Authors:  G J Meissen; R H Myers; C A Mastromauro; W J Koroshetz; K W Klinger; L A Farrer; P A Watkins; J F Gusella; E D Bird; J B Martin
Journal:  N Engl J Med       Date:  1988-03-03       Impact factor: 91.245

Review 9.  Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program.

Authors:  M Bloch; S Adam; A Fuller; B Kremer; J P Welch; S Wiggins; P Whyte; M Huggins; J Theilmann; M R Hayden
Journal:  Am J Med Genet       Date:  1993-09-01

10.  Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease.

Authors:  J Brandt; K A Quaid; S E Folstein; P Garber; N E Maestri; M H Abbott; P R Slavney; M L Franz; L Kasch; H H Kazazian
Journal:  JAMA       Date:  1989-06-02       Impact factor: 56.272

View more
  3 in total

1.  Huntington's Disease and Striatal Signaling.

Authors:  Emmanuel Roze; Emma Cahill; Elodie Martin; Cecilia Bonnet; Peter Vanhoutte; Sandrine Betuing; Jocelyne Caboche
Journal:  Front Neuroanat       Date:  2011-08-23       Impact factor: 3.856

2.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

3.  The Pathogenic Role of Low Range Repeats in SCA17.

Authors:  Jung Hwan Shin; Hyeyoung Park; Gwan Hee Ehm; Woong Woo Lee; Ji Young Yun; Young Eun Kim; Jee-Young Lee; Han-Joon Kim; Jong-Min Kim; Beom Seok Jeon; Sung-Sup Park
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.